[Constrictive pericarditis after inferoposterior myocardial infarction].
Gómez-Barrado
J J
JJ
Vega
J
J
Turégano
S
S
Marcos
G
G
D000077284:Abciximab; D000800:Angioplasty, Balloon; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D006333:Heart Failure / Q000209:etiology; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy / Q000628:therapy; D010490:Pericardial Effusion / Q000139:chemically induced* / Q000150:complications; D010494:Pericarditis, Constrictive / Q000209:etiology*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011183:Postoperative Complications / Q000209:etiology*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications
D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin; D000077284:Abciximab